B
BioOrbit
BioOrbit is space manufacturing company developing hardware for the large-scale crystallisation of protein drugs
About BioOrbit
BioOrbit is a UK-based company specializing in the manufacturing of pharmaceuticals in space. The company focuses on the large-scale crystallization of proteins for monoclonal antibodies (mAbs), with the aim of producing more effective cancer drugs.
By leveraging the microgravity environment of space, BioOrbit intends to overcome some of the limitations of Earth-based pharmaceutical manufacturing. The company is preparing for pre-clinical trials in 2026 for protein crystals produced in its planned orbital factory. The primary market for BioOrbit's products is the pharmaceutical industry, which is constantly seeking to develop more effective treatments for a variety of diseases, including cancer.
The company's business model is centered on research and development, with the ultimate goal of commercializing its space-manufactured pharmaceuticals. This involves securing partnerships with pharmaceutical companies and research institutions to further develop and test its products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- London, United Kingdom
- Employees
- 20
- Open positions
- 2
- Dealroom signal
- 84.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Space Tech, Biotech and Pharma, In-Space Manufacturing, Esa Bic, ESA
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Apr 2026 | $13M | $52M | 7percent Ventures · Seedcamp · Type One Ventures · Auxxo Female Catalyst Fund | ↗ |
| GRANT✓Other financing | Feb 2026 | $330K | — | Government of the United Kingdom | ↗ |
Growth signals
Latest recorded traffic for BioOrbit is 960 monthly website visits, down 54.3% over the last three months. BioOrbit's team grew 42.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
7percent Ventures
Government of the United Kingdom
LocalGlobe
Breega
Seedcamp
Type One Ventures
Auxxo Female Catalyst Fund
Other known investors3 additional known investors
ESA Business Incubation Centre United Kingdom
Seraphim Space
Grow London
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioOrbit on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioOrbit’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.